Literature DB >> 25275706

New insights into immune reconstitution inflammatory syndrome of the central nervous system.

Tory P Johnson1, Avindra Nath.   

Abstract

PURPOSE OF REVIEW: To highlight the importance of immune reconstitution inflammatory syndrome affecting the brain in HIV-infected individuals in the absence of opportunistic infections. To describe the varied clinical manifestations, unifying pathophysiological features and discuss the principles of management of this syndrome. RECENT
FINDINGS: Immune reconstitution inflammatory syndrome within the brain is commonly seen in patients with HIV infection upon initiation of antiretroviral drugs. The fulminant forms occur in the face of opportunistic infections or uncontrolled viral replication within the brain. In this case, the enhanced immune response is targeted against the microbial agent, and the brain suffers bystander damage. Treatment requires the combination of the antimicrobial agent, continued antiretrovirals and in some cases corticosteroids. It is increasingly being recognized that despite adequate control of viral replication in the brain, some patients develop a chronic form of T cell encephalitis which appears to be driven by continued production of HIV-Tat protein. In others, the immune response may be targeted against the host antigens in the brain.
SUMMARY: In patients with central nervous system-immune reconstitution inflammatory syndrome, the use of corticosteroids and strategies that prevent T cell migration into the brain may be needed. Extreme caution is necessary if viral eradication strategies are to be employed that involve activation of viral reservoirs, as these patients may be at risk for developing central nervous system-immune reconstitution inflammatory syndrome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25275706      PMCID: PMC4215804          DOI: 10.1097/COH.0000000000000107

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  76 in total

Review 1.  CROI 2014: Advances in antiretroviral therapy.

Authors:  Barbara S Taylor; Noga Shalev; Timothy J Wilkin
Journal:  Top Antivir Med       Date:  2014-05

2.  Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome.

Authors:  Christina C Chang; Saleha Omarjee; Andrew Lim; Tim Spelman; Bernadett I Gosnell; William H Carr; Julian H Elliott; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Martyn A French; Sharon R Lewin
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

3.  Eradication of HIV from the brain: reasons for pause.

Authors:  Avindra Nath; Janice E Clements
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

4.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Authors:  Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton
Journal:  Neurology       Date:  2014-05-09       Impact factor: 9.910

Review 5.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

6.  HIV stroke risk: evidence and implications.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah L Commins; William Yong; Margrit Carlson
Journal:  Ther Adv Chronic Dis       Date:  2013-03       Impact factor: 5.091

7.  Central nervous system disorders after starting antiretroviral therapy in South Africa.

Authors:  Valerie Asselman; Friedrich Thienemann; Dominique J Pepper; Andrew Boulle; Robert J Wilkinson; Graeme Meintjes; Suzaan Marais
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

8.  Central nervous system immune reconstitution inflammatory syndrome.

Authors:  Nathan Bahr; David R Boulware; Suzaan Marais; James Scriven; Robert J Wilkinson; Graeme Meintjes
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

9.  Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series.

Authors:  Dominique J Pepper; Suzaan Marais; Gary Maartens; Kevin Rebe; Chelsea Morroni; Molebogeng X Rangaka; Tolu Oni; Robert J Wilkinson; Graeme Meintjes
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

10.  The next generation of the World Health Organization's global antiretroviral guidance.

Authors:  Gottfried Hirnschall; Anthony D Harries; Philippa J Easterbrook; Meg C Doherty; Andrew Ball
Journal:  J Int AIDS Soc       Date:  2013-06-30       Impact factor: 5.396

View more
  10 in total

1.  Neurologic Complications in Persons With HIV Infection in the Era of Antiretroviral Therapy.

Authors:  Dennis Kolson
Journal:  Top Antivir Med       Date:  2017 Jul/Aug

2.  Human immunodeficiency virus protein Tat induces oligodendrocyte injury by enhancing outward K+ current conducted by KV1.3.

Authors:  Han Liu; Jianuo Liu; Enquan Xu; Guihua Tu; Minglei Guo; Shangdong Liang; Huangui Xiong
Journal:  Neurobiol Dis       Date:  2016-11-02       Impact factor: 5.996

3.  HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.

Authors:  Ferdous Kadri; Marco Pacifici; Anna Wilk; Amanda Parker-Struckhoff; Luis Del Valle; Kurt F Hauser; Pamela E Knapp; Christopher Parsons; Duane Jeansonne; Adam Lassak; Francesca Peruzzi
Journal:  J Biol Chem       Date:  2015-11-03       Impact factor: 5.157

4.  Lymphocyte-Dominant Encephalitis and Meningitis in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy.

Authors:  Lisa M Mangus; Sarah E Beck; Suzanne E Queen; Samuel A Brill; Erin N Shirk; Kelly A Metcalf Pate; Dillon C Muth; Robert J Adams; Lucio Gama; Janice E Clements; Joseph L Mankowski
Journal:  Am J Pathol       Date:  2017-12-08       Impact factor: 5.770

Review 5.  Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.

Authors:  Ivona Pandrea; Alan Landay; Cara Wilson; Jennifer Stock; Russell Tracy; Cristian Apetrei
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

6.  Anti-N-Methyl-D-Aspartate Receptor Encephalitis in HIV Infection.

Authors:  Eunice Patarata; Vera Bernardino; Ana Martins; Rui Pereira; Conceição Loureiro; Maria Francisca Moraes-Fontes
Journal:  Case Rep Neurol       Date:  2016-12-13

7.  The Role of Human Immunodeficiency Virus-Associated Vasculopathy in the Etiology of Stroke.

Authors:  Laura A Benjamin; Theresa J Allain; Henry Mzinganjira; Myles D Connor; Colin Smith; Sebastian Lucas; Elizabeth Joekes; Sam Kampondeni; Karen Chetcuti; Ian Turnbull; Mark Hopkins; Steve Kamiza; Elizabeth L Corbett; Robert S Heyderman; Tom Solomon
Journal:  J Infect Dis       Date:  2017-09-01       Impact factor: 5.226

Review 8.  Infectious Agents and Stroke: A Systematic Review.

Authors:  Alia Saberi; Shahin Akhondzadeh; Samira Kazemi; Samaneh Kazemi
Journal:  Basic Clin Neurosci       Date:  2021-07-01

9.  Co-occurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Anti-myelin Oligodendrocyte Glycoprotein Inflammatory Demyelinating Diseases: A Clinical Phenomenon to Be Taken Seriously.

Authors:  Yijun Ren; Xiqian Chen; Qiang He; Renchun Wang; Wei Lu
Journal:  Front Neurol       Date:  2019-12-04       Impact factor: 4.003

10.  Lateral amyotrophic sclerosis-like onset after combined antiretroviral treatment initiation.

Authors:  Andres Quevedo-Ramirez; Juan Jose Montenegro-Idrogo; Cristhian Resurrección-Delgado; Blanca Salazar-Mesones; Jorge Gallardo-Cartagena; Gonzalo Cornejo-Venegas; Carolina Méndez-Guerra; Iván Vargas-Matos; Alfredo Chiappe-Gonzalez
Journal:  IDCases       Date:  2020-10-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.